Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease

Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease Cocrystal Lithium-Based Therapy, “LiProSal™” Targets the Reduction of Agitation in Patients with AD Salt Lake City, UT – (Globe Newswire – October 29, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of…

USF/BYRD Institute Announcement

USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders
Alzamend Neuro™ has licensed the USF treatment to help advance commercialization

TAMPA, Fla. – A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention, treatment and cure of Alzheimer’s disease as well as other neurological disorders. This innovative technology has been exclusively licensed from USF to Alzamend Neuro™, Inc.

Chuanhai Cao, a USF associate professor of pharmaceutical sciences and a researcher at the USF Health Byrd Alzheimer’s Institute, has focused his research on peptides for use as a vaccine for Alzheimer’s disease and other neurological diseases.

Dr. Cao has developed an antigen activated immune cell-based vaccine that shows promise in helping combat nervous system dysfunctions in Alzheimer’s disease. Research has shown that the therapeut..

Licenses Patented Alzheimer’s Vaccine

The University of South Florida was granted a patent related to this technology (USPTO # 8,188,046) in 2012, and this patent is exclusively licensed to Alzamend Neuro, a Utah-based pharmaceutical technology company that is dedicated to finding a prevention, treatment and cure for Alzheimer’s disease. The company’s goal is to move this technology out of the research and preclinical stage and into a path toward commercialization.

LINK to Press Release

The post Licenses Patented Alzheimer’s Vaccine appeared first on Alzamend.